



21-22 March 2018, Rotterdam

www.global-engage.com/event/microbiota/



Global Engage's co-located:

5th Microbiome R&D and Business Collaboration Forum & 2nd Probiotics Congress: Europe

The networking forum for the microbiome and probiotic industry

Global Engage is pleased to announce, as part of their worldwide microbiome series, the 5th European Microbiome R&D and Business Collaboration Forum and co-located 2nd Probiotics Congress which will be held on March 21-22, 2018 at the World Trade Center in Rotterdam, the Netherlands. The congress which attracted over 330 attendees in 2017 is the sister meeting to both the popular American and Asian meetings held in San Diego and Singapore which bring together an even split of industry and academic delegates to discuss the latest microbiome science, the development of partnerships and commercial collaborations in this area and the growth of product pipelines.

An increasing awareness of the importance of the role different bacterial ecosystems play with regards to human and animal health has led to a surge in research, publications and companies coming out of the microbiome and probiotic space. As changes in our lifestyle and the growth of multi-drug resistant bacterial strains have also increased the need for better solutions and management of chronic and life-threatening illnesses, microbiome and probiotic research is one of the most scientifically important and potentially lucrative avenues to be exploring. There is mounting evidence that selected probiotic strains can confer health benefits to us especially in digestive diseases and paediatric health and the first microbiome-based drugs will be headed to market in the next few years.

Attracting over 375 attendees, the 14th meeting in the global series will build upon the success of last year's meeting to explore the latest scientific research into the gut, skin, vaginal, oral and lung microbiomes as well as commercial opportunities, pharma and biotech developments, regulation, intellectual property protection, food interactions and pro- and prebiotic research. This will be explored over the two days through a series of interactive presentations with leading academics and industry experts, panel discussions, roundtable discussions and an exhibition area allowing solution providers to showcase their products and services. The Global Engage series is rapidly gaining a fantastic reputation as the number one microbiome networking event for fostering partnerships across academia, pharma and biotech. If looking to either learn more from the top scientists in the microbiome and probiotic space; showcase exciting developments in your research; or seek partnerships and funding within the industry; it is a congress not to be missed!



Speakers and Session Chairs (1 of 2)

**Cathryn Nagler**

Bunning Food Allergy Professor, University of Chicago, USA & Co-Founder and President, ClostraBio

**Jeremy Burton**

Chair in Urological Sciences and is the Deputy Director of the Canadian Centre for Human Microbiome and Probiotics, Lawson Health Research Institute, Canada

**Dirk Haller**

Professor for Nutrition and Immunology, Technical University of Munich, Germany

**Lihi Segal**

CEO,
DayTwo, Israel

**Cath O'Neill**

Senior Lecturer, University of Manchester, UK & CEO, SkinBio Therapeutics

**Greg Fluet**

Chief Business Officer, Rebiotix, USA

**John Zibert**

Chief Medical Officer & Medical Director, Leo Innovation Lab, Denmark

**Egija Zaura**

University Research Chair Professor, VU University Amsterdam, the Netherlands

**Jason Chou**

Team leader for Microbiome and Metabolism, Nestlé Institute of Health Sciences, Switzerland

**Johan van Hylckama Vlieg**

Vice President Microbiome & Human Health Innovation, Chr. Hansen A/S

**Arantxa Lopez**

Postdoctoral Researcher, Alex Mira Lab, Center for Advanced Research in Public Health (CSISP), Spain

**Colin Hill**

Professor of Microbial Food Safety, University College Cork, Republic of Ireland

**Ina Schuppe-Koistinen**

Alliance Director, Center for Translational Microbiome Research, Karolinska Institute, Sweden

**Sarah Lebeer**

Associate Professor Microbiology & Biotechnology, University of Antwerp, Belgium

**Michele Trucksis**

Executive Vice President and Chief Medical Officer, Seres Therapeutics, USA

**Guenolee Prioult [RESERVED]**

Group Leader Food Biotechnology, Nestlé, Switzerland

**Sandrine Claus [RESERVED]**

CSO, Laboratoires Nutrition et Cardiométabolisme (LNC), France

**Rosanna Pecere**

Executive Director, IPA Europe, Belgium



#GEMB18

Speakers and Session Chairs (2 of 2)



Luc Sterkman
CEO, Caelus Health,
the Netherlands



Céline Druart
Assistant Researcher, Louvain Drug Research
Institute, Belgium



Assaf Oron
Chief Business Officer,
BiomX, Israel



Nazima Pathan
Lecturer, University of Cambridge, UK



Kit Wallen Russell
Director of R&D, JooMo Ltd., UK



Gaspar Pérez Martínez
Head of Laboratory of Lactic Acid Bacteria
and Probiotics, IATA-CSIC, Spain



Aletha Kraneveld
Professor in Neuro-
immunopharmacology, Utrecht
University, the Netherlands



Alexandra Zhernakova
Associate Professor, University of Groningen,
the Netherlands



Colette Shortt
Regulatory Director Global Franchise
Organisation- Emerging Science & Open
Innovation, J&J Consumer Care, UK



Gabriele Gross [RESERVED]
Principal Scientist / Project Leader, Global
Discovery R&D, Mead Johnson Nutrition, the
Netherlands



Himanshu Kumar
Senior Scientist, Danone Nutricia
Research, the Netherlands



Patrice Garnier
CEO, Amabiotics, France



Tom van de Wiele
Associate Professor & CRIG Group
Leader, University of Ghent, Belgium



Wouter de Jonge
Professor of NeuroGastroenterology, AMC
Amsterdam, The Netherlands



Mona Bajaj-Elliott
Senior Lecturer, University College
London, UK



Shital Tripathi
Associate Director, Assembly Biosciences, USA



Kirsi Laitinen
Docent, University of Turku, Finland



Todd Krueger
President & CEO, AOBiome, USA



Olaf Larsen
Science Manager, Yakult
Netherlands/Assistant Professor, Vrije
Universiteit Amsterdam



Olga Danilchanka [RESERVED]
Microbiome Lead, Exploratory Science Center,
Merck

Full Agenda – Wednesday 21 March, 2018

08.00-08.45	Registration & Coffee	
08.45-08.50	Global Engage Welcome Address & Morning Chair's Opening Remarks	Global Engage Welcome Address & Morning Chair's Opening Remarks
08.50-09.30	Keynote Presentation: Regulation of Allergic Responses to Food by Commensal Bacteria CONFIRMED: Cathryn Nagler, Bunning Food Allergy Professor, University of Chicago, USA & Co-Founder and President, ClostraBio	Keynote Presentation: The Role of the Microbiome in Urological Health and Treatment The urinary tract was long assumed as sterile in healthy individuals. However, it is now known to harbour a microbiome, and as with any exposed epithelial tissue, the microbiome present is assumed to play a role in maintaining health at this site. The microbiome associated with the urinary system is challenging to index because of its low abundance; there is difficulty when attempting to directly sample above the urethra due to microbial contamination. Studies of the urinary microbiota have identified differences between healthy populations and those with certain conditions, including a potential role in urologic cancers and kidney stones. While the gut microbiome is distant from the urinary system, it may also have a profound effect on urologic health due to its metabolic output and the xenobiotic metabolism of orally ingested urological-targeted medications. New insights into the urinary and intestinal microbiomes of people with urological conditions might provide an opportunity to predict the risk of developing certain diseases and could enable the development of innovative microbiome-based therapeutic strategies. CONFIRMED: Jeremy Burton, Chair in Urological Sciences and is the Deputy Director of the Canadian Centre for Human Microbiome and Probiotics, Lawson Health Research Institute, Canada
09.30-09.55	Personalized Nutrition Based on Gut Microbiome Elevated postprandial (post meal) blood glucose levels are a major risk factor for cardiovascular disease and development of type II diabetes, but current dietary guidelines induce high blood glucose responses in many cases, thereby accelerating development of the metabolic diseases they were intended to treat. Research from the Weizmann Institute in Israel found high variability in individual response to identical meals, with the gut microbiome being a major driver of interpersonal variability. Integrating multi-dimensional data into a machine learning algorithm resulted in successful prediction of individualized post-meal glucose response and algorithm-generated personalized dietary interventions successfully normalized post-meal glucose levels. DayTwo uses and extends the algorithm to provide personalized nutrition and actionable insights that allow people to maintain normal blood sugar levels. CONFIRMED: Lihi Segal, CEO, DayTwo	Understanding Probiotics in a European Context EU rules on nutrition and health claims were established by Regulation (EC) No 1924/2006. Since their entry into force, all requests to put health claims on probiotics have been rejected by EFSA. Furthermore, there is no harmonized approach within the EU regarding the presentation, labelling or advertising of probiotics in food. Consumers are therefore deprived of the information on the characteristics of the food, while at the same time research and innovation in this promising industry is severely stifled. This has led the industry and some member states to reflect on possible solutions and to reshape the future strategies of the probiotic food industry. In the presentation we will set out the legal options, explain the industry's commitment for the use of the word "probiotics" and elaborate on the activity of IPA Europe to find the appropriate way to communicate on probiotics. CONFIRMED: Rosanna Pecere, Executive Director, IPA Europe, Belgium
09.55-10.25	Sponsored Presentation: Title To Be Confirmed Winclove Probiotics is specialized in research, development, and production of probiotic formulations for over 25 years. We closely collaborate with business partners, research institutes and university hospitals to develop indication-specific multispecies probiotics. Our expertise allows us to constantly develop new innovative probiotics substantiated by scientific research. We offer probiotic therapies for the traditional GI therapeutic indications as well as more innovative areas, such as; women's health, mental health and upper respiratory tract infections. Our products are sold by our business partners under private label worldwide. CONFIRMED: Senior Representative, Winclove Probiotics 	Sponsored Presentation For sponsorship opportunities please contact Gavin Hambrook at gavin@globalengage.co.uk
10.25-10.55	Odd-Numbered Poster Presentation Session Grab a refreshment and head over to view a wide selection of posters. A full poster abstract book can be viewed online prior to the congress and a summary of posters is viewable at the bottom of the agenda	
10.55-11.35	Morning Refreshments Scheduled One-to-One Meetings	

	Microbiome Drug Development	Skin Microbiome	Probiotics Congress
11.35-12.00	Title To Be Confirmed RESERVED: Olga Danilchanka, Microbiome Lead, Exploratory Science Center, Merck, USA	Effects of Dietary Changes in Psoriasis Patients based on their Microbiome Profiling CONFIRMED: John Zibert, Chief Medical Officer & Medical Director, Leo Innovation Lab, Denmark	European Food Regulatory Landscape for Pre/Probiotics: Quo Vadis? CONFIRMED: Colette Shortt, Regulatory Director Global Franchise Organisation- Emerging Science & Open Innovation, J&J Consumer Care, UK
12.00-12.25	Title To Be Confirmed RESERVED: Sandrine Claus, CSO, Laboratories Nutrition et Cardmétabolisme (LNC), France	The Gut-Skin Axis in Health and Disease CONFIRMED: Cath O'Neill, Senior Lecturer, University of Manchester, UK & CEO, SkinBio Therapeutics	Title To Be Confirmed CONFIRMED: Himanshu Kumar, Senior Scientist, Danone Nutricia Research, the Netherlands
12.25-12.50	Title To Be Confirmed CONFIRMED: Jason Chou, Team leader for Microbiome and Metabolism, Nestlé Institute of Health Sciences, Switzerland	Title To Be Confirmed Skin Microbiome and Cosmetics CONFIRMED: Kit Wallen Russell, Director of R&D, JooMo Ltd.	Title To Be Confirmed CONFIRMED: Sarah Lebeer, Associate Professor Microbiology & Biotechnology, University of Antwerp, Belgium
12.50-13.20	Sponsored Presentation: Title To Be Confirmed Clinical-Microbiomics is a world leading contract research organization specialized in microbiome metagenomics. Through state-of-the-art sequencing and development of tailor-made bioinformatics tools, we assist partners across pharmaceutical, food, nutritional and agricultural industries to extract key biological insights from microbiome research. Our proprietary bioinformatics toolbox and continuous innovation pipeline provides our partners with unmatched capabilities to analyze and interpret microbiome metagenomics, including proven track-record of integration of big data, such as metabolomics, metatranscriptomics and clinical data. With a unique partnering approach, our microbiome experts guide and optimize your study from experimental design to final analysis and interpretation. We are committed to sharing our knowledge and expertise and will thoroughly review all findings with you to provide actionable microbiome insights to accelerate your research. CONFIRMED: Senior Representative, Clinical Microbiomics 	Sponsored Presentation For sponsorship opportunities please contact Gavin Hambrook at gavin@globalengage.co.uk	Sponsored Presentation For sponsorship opportunities please contact Gavin Hambrook at gavin@globalengage.co.uk
13.20-14.20	Lunch		

14.20-14.45	Microbiome Therapeutics: Rethinking Medical Therapy CONFIRMED: Michele Trucksis, Executive Vice President and Chief Medical Officer, Seres Therapeutics, USA	The Host and its Oral Microbiome The human microbiome has evolved in symbiosis with its host for thousands of years. This has resulted in highly efficient host-bacterial mutualism. Hundreds of bacterial taxa and other microorganisms interact with each other and with their environment, which is provided by the host. It is known that genetic and behavioural factors of the host are shaping the microbiome. In this talk the current knowledge on the role of the host factors such as salivary properties, gender, dietary and behavioural habits of the host, as well as general health of the host on the oral microbiome and oral health will be discussed. CONFIRMED: Egija Zaura, University Research Chair Professor, VU University Amsterdam, the Netherlands	Biotechnological Development of Peptide Domains from Probiotic Bacteria that Stimulate Intestinal Epithelial Proliferation and Repair Two secreted multifunction proteins of the probiotic strains L.casei BL23 and L.rhamnosus GG (p40 and p75) have been reported to have antiapoptotic and IgA stimulating features. They are autolysins containing an active C-terminal domain of the NLPc/P60 family. Their genes have been cloned, deleted and the proteins purified to determine the smallest fragment retaining biological activity and affinity for cell surface components. New intriguing properties of these proteins have been revealed through the study of the internalization of whole bacterial cells into intestinal epithelial cells. Finally, surface Plasmon Resonance affinity assays and intestinal epithelial cell responses suggested that both proteins may have different receptors or mediators and that the N-terminus region is involved in the biological activity of these proteins. CONFIRMED: Gaspar Pérez Martínez, Head of Laboratory of Lactic Acid Bacteria and Probiotics, IATA-CSIC, Spain
14.45-15.10	BiomX – Novel Therapeutics through Microbiome Modulation Since 2015, BiomX has been developing innovative microbiome-based therapeutics to prevent and treat cancer, IBD, and skin disorders that stem from microbiome dysbiosis. The Company's microbiome modulation platform uses cutting-edge science and licensed technology created by its founders, Professor Rotem Sorek, Ph.D., and Prof. Eran Elinav, M.D./Ph.D., both of The Weizmann Institute; and Professor Timothy K. Lu, M.D./Ph.D., of The MIT. BiomX most advanced product candidates include BX001 for acne and BX002 for IBD both at preclinical development stages. BX002 is a phage cocktail eradicating several proprietary bacteria targets associated with the onset of IBD and provides a unique therapeutic approach to the disease. Investors in the Company include OrbiMed Israel Incubator LP, Johnson & Johnson Development Corporation Inc., Takeda Ventures, Inc., Seventure Partners, Mirae Asset Global Investments, private Swiss investors and SBI. CONFIRMED: Assaf Oron, Chief Business Officer, Biomx, Israel	Health-Associated Niche Inhabitants as Oral Probiotics Oral diseases, including dental caries and periodontitis, are among the most prevalent diseases worldwide and develop as a consequence of a microbial dysbiosis. Several bacterial strains are being tested as potential oral health-promoting organisms, but usually they are species isolated from niches other than the site where they must exert its probiotic action. We hypothesize that oral inhabitants associated to health conditions will be more effective than traditional, gut-associated probiotic species in key aspects such as colonization of the oral site where disease takes place or the possession of oral health promoting functions. As an example of these <i>active colonizers</i> , we describe the case of <i>Streptococcus dentisani</i> , a new streptococcal species isolated from dental plaque of caries-free individuals with a double probiotic action, as it inhibits the growth of major oral pathogens through the production of bacteriocins, and also buffers acidic pH (the primary cause of dental caries) through an arginolytic pathway. CONFIRMED: Arantxa Lopez, Postdoctoral Researcher, Alex Mira Lab, Center for Advanced Research in Public Health (CSISP), Spain	Title To Be Confirmed CONFIRMED: Olaf Larsen, Science Manager, Yakult Nederland B.V
15.10-15.35	Title To Be Confirmed RESERVED: Senior Representative, Janssen Human Microbiome Institute	Title To Be Confirmed Oral Microbiome RESERVED:	Title To Be Confirmed We focus on the use of complementary <i>in vitro</i> (simple and complex <i>in vitro</i> models and <i>in vivo</i> approaches to investigate the antimicrobial effect of probiotic yeast against enterotoxigenic E. coli (ETEC) which are responsible of traveller's diarrhoea and infant diarrhoea in developing countries. In particular we use complex <i>in vitro</i> models of the human gut (TIM, SHIME) to better understand the effect of probiotics on ETEC survival, physiological state and regulation of virulence genes in the human simulated gastro-intestinal tract. RESERVED: Stéphanie Blanquet-Diot, Associate professor, EA CIDAM, University of Auvergne, France
15.35-16.05	Sponsored Presentation: Title To Be Confirmed  CONFIRMED: Senior Representative, Novogene	Sponsored Presentation For sponsorship opportunities please contact Gavin Hambrook at gavin@globalengage.co.uk	Sponsored Presentation For sponsorship opportunities please contact Gavin Hambrook at gavin@globalengage.co.uk
16.05-16.55	Afternoon Refreshments Scheduled One-to-One Meetings		

16.55-17.10	Company Showcase For sponsorship opportunities please contact Gavin Hambrook at gavin@globalengage.co.uk	Company Showcase For sponsorship opportunities please contact Gavin Hambrook at gavin@globalengage.co.uk
17.10-17.35	Title To Be Confirmed CONFIRMED: Shital Tripathi, Associate Director, Assembly Biosciences, USA	Roundtable Discussions: TABLE 1 - SECURING FUNDING Cath O'Neill, Senior Lecturer, University of Manchester, UK & CEO, SkinBio Therapeutics • What are investors looking for? • • TABLE 2 - IP PROTECTION TBC • Categories of microbiome therapeutics • Strategies for patenting • Challenges in the regulatory landscape TABLE 3 – INDUSTRY-ACADEMIC COLLABORATIONS Ina Schuppe-Koistinen, Alliance Director, Center for Translational Microbiome Research, Karolinska Institute • Structuring successful collaborations • Case study examples • Spin-outs TABLE 4 – Microbiome Development from Laboratory to Clinical Lead Luc Sterkman, CEO, Caelus Health • Fecal microbiota transplant studies • Selection of donors • Identification of microbiome leads for further development • Lead evaluation – key aspects to consider • Lead optimisation – mutagenesis and/or CRISPR/CAS • Formulation development
17.35-18.00	Translational development of Akkermansia to target metabolic disorders: from mice to human Who is <i>Akkermansia muciniphila</i>? Brief overview of a bacterium considered as a next generation beneficial microbes and summary of more than 10 years of investigation from mice to man: • 2004: discovery of Akkermansia muciniphila by Willem de Vos team. • 2007: food impact on the abundance of Akkermansia, role of fat versus fibers • 2013: demonstration that Akkermansia reduces diet-induced obesity, fat mass development, diabetes and gut barrier dysfunction in mice • 2015: first administration of Akkermansia in humans : the Microbes4U study starts in Belgium • 2017: pasteurized Akkermansia and the newly discovered protein Amuc_1100 isolated from Akkermansia abolished diet-induced weight gain fat mass, liver fat and inflammation, hypercholesterolemia and normalized gut barrier. • 2017: proof of the safety of live and pasteurized A. muciniphila administration in human • 2018: Wat's next? CONFIRMED: Céline Druart, Assistant Researcher, Louvain Drug Research Institute, Belgium	
18.00-19.00	Complimentary Drinks Reception If you would be interested in sponsoring the drinks reception please contact Gavin Hambrook at gavin@globalengage.co.uk	

Full Agenda – Thursday 22 March, 2018

08.00-08.40	Coffee and Refreshments		
	Microbiome Forum	Probiotics Congress	
08.40-08.45	Morning Chair's Opening Remarks	Morning Chair's Opening Remarks Geertrui Vlaemynck, Researcher, Technology & Food, ILVO	
08.45-09.25	Keynote Presentation: Functional Relevance of Microbiome Signatures – Inflammation Meets Colon Cancer • Transfer studies of human microbiota in germfree mouse models • Transfer studies of dysbiotic microbiota in IBD and cancer models • Identification of pathobionts relevant for IBD and colon cancer • Identification of host target mechanisms in inflammation and colon cancer CONFIRMED: Dirk Haller, Professor for Nutrition and Immunology, Technical University of Munich, Germany	Keynote Presentation: Bacteriocin Production by Probiotics, a Key Trait in Probiotic Functionality A key objective in probiotic research is the identification of the mechanistic basis of observed health effects. Bacteriocin production is one of the few properties that has been unequivocally identified in terms of the molecular basis of a probiotic trait – resistance to infection. Once a probiotic trait has been identified, screening programmes can be adapted to identify potentially probiotic strains, or to probe the mechanistic basis of existing probiotic strains. In this presentation I will present several examples where bacteriocin production can be linked to health benefits, providing a discovery pipeline which can be adapted for other probiotic traits. CONFIRMED: Colin Hill, Professor of Microbial Food Safety, University College Cork, Republic of Ireland	
09.25-09.50	Title To Be Confirmed CONFIRMED: Johan van Hylckama Vlieg, Vice President Microbiome & Human Health Innovation, Chr. Hansen A/S	Interactions among Diet, Microbiota and Metabolism in Advancing the Health of Overweight Pregnant Women Overweight during pregnancy predisposes both the mother and foetus to health complications. Maternal complications include an increased risk of gestational diabetes and type 2 diabetes in years to come. Both diet and human gut microbiota are known to contribute to the health by regulating the host metabolism. Although the adult gut microbiota is generally considered consolidated, external factors, such as diseases and diet, may modify the composition and activity of the gut ecosystem. It is also possible that some metabolic effects of diet are mediated through gut microbiota. In other words, diet and gut microbiota both have direct effects on metabolism and human health, but gut microbiota may also act as a metabolic link between the diet and the host health. The diet-microbiota-metabolism relationships during pregnancy are mostly unknown but may underlie the clinical health outcomes. We have explored these relations in a randomized mother-child intervention trial involving probiotics and long-chain polyunsaturated fatty acids. CONFIRMED: Kirsi Laitinen, Docent, University of Turku, Finland	
09.50-09.55	Gut Microbiome	Outside the Gut	Probiotics Congress
09.55-10.25	Sponsored Presentation For sponsorship opportunities please contact Gavin Hambrook at gavin@globalengage.co.uk	Sponsored Presentation For sponsorship opportunities please contact Gavin Hambrook at gavin@globalengage.co.uk	Sponsored Presentation For sponsorship opportunities please contact Gavin Hambrook at gavin@globalengage.co.uk
10.25-10.55	Even-Numbered Poster Presentation Session Grab a refreshment and head over to view a wide selection of posters. A full poster abstract book can be viewed online prior to the congress and a summary of posters is viewable at the bottom of the agenda		
10.55-11.35	Morning Refreshments Scheduled One-to-One Meetings		

	Gut Microbiome		Probiotics Congress
11.35-11.50	Company Showcase: Title To Be Confirmed Applying the latest technology and information regarding the human gut microbiome, Bio-Me develops novel tools to analyze the composition of the gut microbiome in a rapid, reproducible, high throughput and affordable way.  RESERVED: Morten Isaksen, CEO, Bio-Me	Company Showcase: Title To Be Confirmed It is our objective to develop and provide the most comprehensive set of tools for DNA, RNA, and epigenetic research available today. Thousands of peer-reviewed scientific publications from researchers feature our technologies. Through innovation, our scientists have made the only comprehensive solution for Microbiomics and Metagenomics possible, developed the simplest and most sophisticated methods for plasmid DNA purification, and patented the first RNA purification directly from Trizol® without phase separation among many other leading technologies.  CONFIRMED: Sarah Hemmasi, Research Associate, Zymo Research Europe GmbH	Company Showcase: Title To Be Confirmed Clinical-Microbiomics is a world leading contract research organization specialized in microbiome metagenomics. Through state-of-the-art sequencing and development of tailor-made bioinformatics tools, we assist partners across pharmaceutical, food, nutritional and agricultural industries to extract key biological insights from microbiome research. Our proprietary bioinformatics toolbox and continuous innovation pipeline provides our partners with unmatched capabilities to analyze and interpret microbiome metagenomics, including proven track-record of integration of big data, such as metabolomics, metatranscriptomics and clinical data. With a unique partnering approach, our microbiome experts guide and optimize your study from experimental design to final analysis and interpretation. We are committed to sharing our knowledge and expertise and will thoroughly review all findings with you to provide actionable microbiome insights to accelerate your research.  CONFIRMED: Senior Representative, Clinical Microbiomics
11.50-12.15	Title To Be Confirmed CONFIRMED: Tom van de Wiele, Associate Professor & CRIG Group Leader, University of Ghent, Belgium	The Microbiome: Interaction of Genes, Food, and Environment CONFIRMED: Alexandra Zhernakova, Associate Professor, University of Groningen, the Netherlands	Title To Be Confirmed RESERVED: David Orbis, Probiotics Strategy Leader, Research & Innovation, Danone Nutricia Research, France
12.15-12.40	Panel Discussion: Growing a Microbiome Business - Examining the challenges of growing a microbiome business - Growing microbiome focus and expertise within established companies - Structuring collaborations	Roundtable Discussions: TABLE 1 –MAKING SENSE OF MICROBIOME DATA - Tools to analyse microbiome data - Generating data from the public - How do we make meaningful use of data TABLE 2 – MICROBIOME AND CANCER IMMUNOTHERAPY - Understanding the microbiome in immunotherapy - Innovation in immunotherapy-microbiome research - Using the microbiome to predict response - Future Directions TABLE 3 – GUT-BRAIN CONNECTIONS	Title To Be Confirmed Prebiotics RESERVED: Guenolee Prioult, Group Leader Food Biotechnology, Nestlé, Switzerland
12.40-13.05	CONFIRMED: Todd Krueger, President, AOBiome Greg Fluet, Chief Business Officer, Rebiotix Senior Representative, Seres Therapeutics X2 Industry Representatives		Title To Be Confirmed Prebiotics RESERVED: Gabriele Gross, Principal Scientist / Project Leader, Global Discovery R&D, Mead Johnson Nutrition, the Netherlands

13.05-14.05	Lunch		
14.05-14.35	Sponsored Presentation For sponsorship opportunities please contact Gavin Hambrook at gavin@globalengage.co.uk	Sponsored Presentation For sponsorship opportunities please contact Gavin Hambrook at gavin@globalengage.co.uk	Sponsored Presentation For sponsorship opportunities please contact Gavin Hambrook at gavin@globalengage.co.uk
14.35-15.00	The Microbiota Directing Functional and Inflammatory Bowel Disease-Future Challenges - The state of the art in the functional role of microbiota dysbiosis in IBS and IBD, our learnings from FMT studies and preclinical work - Metabolic activity of microbiota relating to epithelial barrier function and mucosal tolerance - Molecular pathways explaining how luminal metabolites can fortify mucosal tolerance in early life, and the relevance of those findings for design of optimal neonatal nutrition CONFIRMED: Wouter de Jonge, Professor of NeuroGastroenterology, AMC Amsterdam, the Netherlands	Title To Be Confirmed RESERVED: Senior Representative, NIZO	Probiotics modulate the vitamin receptor-autophagy signaling pathways Vitamin D receptor (VDR) plays an essential role in pathogenesis of various human diseases, including inflammatory bowel disease (IBD). Our recent study (Wang, et al, <i>Nature Genetics</i> , 2016) has demonstrated that human VDR is a key host factor to shape gut microbiome. Further, our study has demonstrated that intestinal epithelial VDR conditional knockout (VDR ^{ΔIEC}) leads to dysbiosis. Low expressions of VDR is associated with impaired autophagy, accompanied by a reduction of ATG16L1 and LC3B (Wu, et al, <i>Gut</i> , 2015). Here, we highlight the beneficial effects of probiotic <i>Lactobacillus</i> strains, isolated from Korean Kimchi, in upregulating VDR signaling and autophagic responses and suppressing inflammation. Our data indicate novel therapeutic and beneficial roles of probiotics in inhibiting inflammation and infection. CONFIRMED: Jun Sun, Associate Professor, University of Illinois at Chicago
15.00-15.25	Title To Be Confirmed Gut-Brain Axis CONFIRMED: Aletta Kraneveld, Professor in Neuro-immunopharmacology, Utrecht University, the Netherlands	Causes and Consequences of <i>Clostridium difficile</i> Colonisation in Hospitalised Children <i>Clostridium difficile</i> is the leading cause of antibiotic-associated diarrhoea worldwide. In adults (>65 years of age), <i>C. difficile</i> infection and associated diseases (CDI/CDAD) represent a significant burden of morbidity and mortality. The depletion of normal healthy microbiota in conjunction with bacterial toxin-secretion invariably promotes gastrointestinal (GI) pathology in CDAD. Although details remain unclear, disease remission seen in response to faecal transplantation, confirms the importance of the microbiome in curbing the assault by this enteropathogen. Neonates and children under the age of two can be heavily colonised with <i>C. difficile</i> , with the rates of colonisation declining to adult levels above 2 years of age. The impact of <i>C. difficile</i> colonisation on GI homeostasis in the paediatric population has not been studied, although recent studies do implicate increased risk of food allergy in <i>C. difficile</i> carriers. I will present our early findings on the potential effect of <i>C. difficile</i> on the paediatric GI tract. CONFIRMED: Mona Bajaj-Elliott, Senior Lecturer, University College London, UK	
15.25-15.50	Translating Microbiome Science into Effective Innovative Therapies - Microbiome-based Therapies: a large set of strategies! - A successful example: AMA-101, a potential first-in-class therapy for Parkinson's disease. - Microbiome Indication-screening process: a new paradigm for drug discovery - Microbiome-derived Diagnostics: a way for personalized medicine? CONFIRMED: Patrice Garnier, CEO, Amabiotics, France	The Gut Microbiome in Critical Illness - Dysbiosis and Metabolic Dysfunction Critical illness is associated with significant morbidity and is a costly healthcare burden. The intestinal microbiome makes many contributions to host physiology including fermentation, immune, metabolic and endocrine activities. Dysbiosis of the microbiome in critical illness is likely due to iatrogenic factors as well as disease pathophysiology. The microbiome of critically ill individuals suffers profound depletion of species associated with intestinal health, and relative collapse of the trophic fermentation network. The faecal microbiome in critical illness is characterised by loss of fermentative commensals and producers of host-beneficial co-metabolites. This correlates with marked reduction in measured levels of beneficial bacterial co-metabolites, alongside increased abundance of metabolic intermediates. This is likely to impact on wider organ dysfunction including severity of lung injury and cardiovascular compromise. CONFIRMED: Nazima Pathan, Lecturer, University of Cambridge, UK	
15.50-16.20	Afternoon Refreshments		

